Scott Carmer vice president, sales and marketing, Rituxan immunology...and Mary Sliwkowski vice president, regulatory affairs, chemistry manufacturing and controls

and it added four other new vice presidents: Allan Darling for corporate quality control, Garry Ebbert for antibody and small-molecule manufacturing, Bahija Jallal for translational sciences, and Douglas Willner for sales training...Mersana, of Cambridge, Mass., appointed Russell Petter vice president of research and Ullrich Schwertschlag vice president of clinical development

Infinity Pharmaceuticals Inc., of Cambridge, Mass., appointed Julian Adams president and chief scientific officer, Adelene Perkins executive vice president and chief business officer, and David Grayzel vice president, clinical development and medical affairs

Wayne Frost vice president, regulatory affairs and quality assurance...MicroIslet Inc., of San Diego, appointed James Gavin interim president and CEO...Pharmacopeia, of Princeton, N.J., said its president and CEO, Leslie Browne, was appointed to the board of trustees of the Biotechnology Council of New Jersey

Celsion Corp., of Columbia, Md., appointed William Hahne vice president clinical development and medical affairs, and Christopher Black executive director, preclinical research...and Jennifer Cook Williams to vice president, investor relations

UCB, of Brussels, Belgium, appointed Bill Robinson and Bob Trainor as new members of the company's executive committee...Vivus Inc., of Mountain View, Calif., appointed Wesley Day vice president of clinical development

Quaker BioVentures, of Philadelphia, promoted Matt Rieke and Richard Kollender to partner, and Geeta Vemuri to vice president...Serenex Inc., of Durham, N.C., appointed Virgil Lucas vice president, clinical development

Microbia Inc., of Cambridge, Mass., appointed Jeffrey Johnston vice president, clinical development and chief medical officer...NPS Pharmaceuticals, of Salt Lake City, appointed Anthony Coles president and chief operating officer

and Joseph Sarret corporate counsel and director, business development...Paul Chang chief medical officer, and vice president, regulatory affairs and clinical development

Cell Therapeutics Inc., of Seattle, promoted Jade Brown to executive vice president and chief business officer, and Scott Stromatt to executive vice president, clinical development and regulatory affairs

VaxGen Inc., of Brisbane, Calif., appointed Eve Slater and Kevin Reilly to its board...ViaCell Inc., of Boston, appointed Paul Blake and James Sigler to its board...ZymoGenetics Inc., of Seattle, appointed Nicole Onetto chief medical officer and senior vice president

NicOx SA, of Sophia-Antipolis, France, appointed Maarten Beekman vice president of clinical development, Ali Raza and Stefano Bionid director of the research laboratories, and promoted Ennio Ongini to vice president of research...Revance Therapeutics, of Mountain View, Calif., appointed Mary Spellman senior vice president of clinical development, Jane Moffitt senior vice president of regulatory affairs, and Bobby Purkait senior vice president of R&D and operations

and Michael Varney vice president, small-molecule drug discovery...MacroGenics Inc., of Rockville, Md., appointed Nelson Campbell and Ronald Wilder to its senior management team, and promoted Ezio Bonvini to vice president of research, and Joseph Panigot to vice president of legal affairs...NeoRx Corp., of Seattle, appointed David Karlin senior vice president of clinical development and regulatory affairs

The company also added Julia Haller as a clinical consultant and adviser...Altus Pharmaceuticals Inc., of Cambridge, Mass., appointed Alan Kimura vice president, clinical development and medical affairs...Anacor Pharmaceuticals, of Palo Alto, Calif., appointed Richard Markham and Anders Hove to its board

Gabe Leung executive vice president and president of oncology...Jonathan Rachman vice president of clinical development for the diabetes/obesity team...and Karsten Witt senior medical officer for drug safety

Halozyme Therapeutics Inc., of San Diego, appointed Richard Yocum vice president of clinical development and medical affairs...Illumina Inc., of San Diego, appointed Scott Kahn vice president and chief information officer, and Paul Grint to its board

Neurorecovery Inc., of Tuscaloosa, Ala., appointed Ben Labry and James Terwilliger to oversee business development and marketing activities...Prosidion Ltd., of Oxford, UK, appointed Jonathan Rachman vice president of clinical development

Generex Biotechnology Corp., of Toronto, appointed Mindy Allport-Settle and Peter Amanatides to its regulatory compliance committee...Imagenetix Inc., of San Diego, formed a scientific and medical advisory board to include Jonathan Adachi, Dan Gallaher and Robert Beeten

Biocom, of San Diego, appointed Jack Lief chairman and added new board members Dana Di Ferdinando, Larry Fitch, Mary Lyons, Randall Woods and Kleanthis Xanthopoulos...Theratechnologies Inc., of Montreal, appointed James Sutton vice president, clinical development and regulatory affairs, and Robert Goyer to its board